Amicus Therapeutics Inc.
Amicus Therapeutics Reports Strong Q1 2024 Results and Raises Full-Year Guidance
Summary
Amicus Therapeutics, Inc. reported total revenue of $110.4 million for the first quarter of 2024, marking a 28% year-over-year increase. The company attributed the growth to strong performance in its Galafold product, which saw a 15% increase in net product sales. Amicus also noted a significant uptake in its newly launched Pombiliti + Opfolda therapy, with over 155 patients on treatment. The company raised its full-year 2024 revenue guidance to a range of 25%-30% and reiterated its expectation of achieving non-GAAP profitability for the year. Amicus will discuss these results in a conference call and webcast on May 9, 2024.
Profitelligence Alerts
Get alerts for FOLD
Be first to know when Amicus Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Amicus Therapeutics Inc.
Amicus Therapeutics Inc. is a biopharmaceutical company dedicated to developing advanced therapies for rare and orphan diseases. Its primary focus is on genetic disorders, particularly lysosomal storage disorders and other diseases resulting from improper protein folding within cells. Amicus leverages its proprietary technology platforms to create drug candidates that address unmet medical needs, providing innovative solutions for complex conditions like Fabry disease and Pompe disease. The company's commitment to patient-centric innovation aims to enhance the quality of life for individuals facing challenging health diagnoses. Situated within the biotechnology sector, Amicus plays a significant role in advancing novel treatment options, thereby impacting healthcare markets and potentially transforming the standard of care for rare genetic diseases. Founded in 2002, the company harnesses cutting-edge research and collaborations to foster groundbreaking developments in the therapeutic landscape uniquely shaped by the complexities of rare diseases.
Official SEC Documents
Advertisement